HLA diversity is associated with TKI response and treatment‐free remission in chronic myeloid leukemia
Charles Toulemonde(Hôpital Lyon Sud), Vincent Alcazer(Lyon 1 Université), Christophe Bouvier(Inserm), Valérie Dubois(Établissement Français du Sang), Fiorenza Barraco(Hôpital Lyon Sud), Julien Bollard(Université Claude Bernard Lyon 1), Gaëlle Fossard(Hospices Civils de Lyon), Hélène Labussière‐Wallet(Hospices Civils de Lyon), M. Michallet(Hospices Civils de Lyon), Franck‐Emmanuel Nicolini(Centre Léon Bérard), Sandrine Hayette(Hôpital Claude Huriez), Julie Hildt(Inserm), Alexandre Ridao(Hôpital Lyon Sud), Sophie Ducastelle(Hôpital Lyon Sud), Marie‐Claire Archier(Hôpital Lyon Sud), Marie Balsat(Hôpital Claude Huriez)
Cited by 2
Related Papers
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
|Blood|2015|377
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
|Blood|2016|329
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309